Last Close
Apr 08  •  04:00PM ET
9.85
Dollar change
+0.18
Percentage change
1.86
%
Index
RUT
P/E
157.10
EPS (ttm)
0.06
Insider Own
2.90%
Shs Outstand
34.69M
Perf Week
6.14%
Market Cap
342.25M
Forward P/E
-
EPS next Y
-0.20
Insider Trans
2.17%
Shs Float
33.74M
Perf Month
8.00%
Enterprise Value
252.15M
PEG
-
EPS next Q
-0.09
Inst Own
49.40%
Perf Quarter
-5.74%
Income
2.70M
P/S
4.02
EPS this Y
-961.22%
Inst Trans
-3.75%
Perf Half Y
-8.80%
Sales
85.23M
P/B
3.07
EPS next Y
67.54%
ROA
2.26%
Perf YTD
-2.48%
Book/sh
3.21
P/C
3.76
EPS next 5Y
33.66%
ROE
3.00%
52W High
18.23 -45.97%
Perf Year
-5.20%
Cash/sh
2.62
P/FCF
16.32
EPS past 3/5Y
- -
ROIC
2.41%
52W Low
8.12 21.31%
Perf 3Y
74.34%
Dividend Est.
-
EV/EBITDA
249.66
Sales past 3/5Y
215.30% 120.21%
Gross Margin
86.16%
Volatility
3.37% 3.57%
Perf 5Y
-27.41%
Dividend TTM
-
EV/Sales
2.96
EPS Y/Y TTM
107.92%
Oper. Margin
0.77%
ATR (14)
0.37
Perf 10Y
-100.00%
Dividend Ex-Date
-
Quick Ratio
9.98
Sales Y/Y TTM
129.08%
Profit Margin
3.17%
RSI (14)
59.26
Dividend Gr. 3/5Y
- -
Current Ratio
10.92
EPS Q/Q
50.99%
SMA20
4.85%
Beta
0.49
Payout
0.00%
Debt/Eq
0.01
Sales Q/Q
37.27%
SMA50
4.08%
Rel Volume
0.67
Prev Close
9.67
Employees
156
LT Debt/Eq
0.01
SMA200
-4.94%
Avg Volume
455.96K
Price
9.85
IPO
Oct 23, 2001
Option/Short
Yes / Yes
Trades
Volume
306,717
Change
1.86%
Date Action Analyst Rating Change Price Target Change
Jun-28-24Initiated Craig Hallum Buy $18
May-14-24Initiated Stephens Overweight $25
Jul-26-22Resumed Canaccord Genuity Buy $17
Dec-10-21Initiated H.C. Wainwright Buy $25
Mar-09-21Initiated Canaccord Genuity Buy $24
Jan-05-21Initiated BTIG Research Buy $23
Jun-01-20Initiated Laidlaw Buy $19
Apr-06-26 08:30AM
Apr-01-26 08:30AM
Mar-04-26 08:43AM
Mar-03-26 08:00AM
Feb-26-26 04:09PM
03:48PM Loading…
03:48PM
08:30AM
08:00AM
Feb-12-26 08:00AM
Feb-11-26 03:15PM
Jan-27-26 08:05AM
Jan-21-26 04:01PM
Jan-09-26 08:05AM
Jan-02-26 08:38AM
Jan-01-26 08:15AM
08:00AM Loading…
Dec-31-25 08:00AM
Dec-16-25 10:25AM
Dec-03-25 04:01PM
Nov-24-25 08:36AM
Nov-20-25 04:01PM
Nov-18-25 08:00AM
05:07AM
Nov-14-25 04:01PM
Nov-13-25 08:30AM
Nov-06-25 04:01PM
Nov-04-25 04:06PM
09:15AM
08:00AM
Oct-27-25 04:43PM
Oct-21-25 08:30AM
04:15PM Loading…
Oct-18-25 04:15PM
04:13PM
Sep-22-25 04:01PM
Sep-05-25 04:01PM
Sep-04-25 02:52PM
Aug-21-25 08:30AM
Aug-19-25 08:30AM
Aug-13-25 12:08PM
Aug-06-25 09:15AM
08:00AM
Jul-29-25 04:01PM
Jul-28-25 05:15PM
Jul-25-25 04:01PM
Jul-23-25 04:01PM
Jul-17-25 08:32AM
Jun-04-25 12:00PM
09:40AM
May-28-25 09:55AM
08:50AM
May-22-25 07:00AM
May-15-25 04:30PM
May-09-25 05:30PM
03:15AM
May-08-25 08:45AM
07:30AM
May-07-25 06:00PM
02:21PM
May-06-25 07:10AM
Apr-28-25 08:30AM
Apr-27-25 09:22AM
Apr-24-25 04:01PM
Apr-10-25 09:03AM
Apr-09-25 05:00PM
Apr-02-25 11:49AM
Mar-27-25 04:45PM
10:46AM
Mar-26-25 09:55AM
Mar-24-25 04:01PM
Mar-19-25 09:40AM
Mar-14-25 04:01PM
Mar-06-25 08:00AM
Feb-20-25 08:30AM
Feb-14-25 08:30AM
Jan-31-25 07:00AM
Jan-28-25 04:01PM
Jan-15-25 02:31PM
Jan-13-25 08:00AM
Jan-03-25 04:01PM
Dec-30-24 08:00AM
Dec-02-24 08:30AM
Nov-09-24 04:00PM
Nov-08-24 08:00AM
Nov-01-24 04:01PM
Oct-25-24 08:30AM
Oct-17-24 08:30AM
Sep-20-24 04:01PM
Sep-16-24 08:30AM
Aug-28-24 04:01PM
04:01PM
Aug-27-24 08:30AM
Aug-26-24 04:01PM
Aug-20-24 08:30AM
Aug-12-24 04:01PM
Aug-05-24 08:59PM
04:01PM
08:30AM
Jul-30-24 04:01PM
Jul-22-24 04:01PM
Jul-15-24 12:00PM
Jun-14-24 08:50AM
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pennell SandraChief Financial OfficerMar 06 '26Buy9.045,53350,01877,018Mar 06 04:22 PM
Sylvester John RichardDirectorNov 21 '25Buy8.894,38638,99214,936Nov 25 04:15 PM
MICHEL GERARD JCHIEF EXECUTIVE OFFICERNov 11 '25Buy8.5311,50098,049330,834Nov 13 11:53 AM
Vukovic VojoCHIEF MEDICAL OFFICERJun 12 '25Option Exercise4.7842,000200,760168,882Jun 13 05:22 PM